Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.

S, Hwang; AY, Kwon; JY, Jeong; S, Kim; H, Kang; J, Park; JH, Kim; OJ, Han; SM, Lim; HJ, An

doi:10.1038/s41598-019-57218-9

Public

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.

Shared by NobleBlocks on Jan 20, 2020 • 12:00 AM UTC

Authors:

Hwang S

Kwon AY

Jeong JY

Abstract

Immune checkpoint blockade is promising for treating non-small-cell lung cancer (NSCLC). We used multipanel markers to predict the response to immune checkpoint inhibitors (ICIs) by characterizing gene expression signatures or individual genes in patients who showed durable clinical benefit to ICIs....

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!